FDA Clears Path to Clinic Without Additional IND-Enabling Toxicology studies
AliquantumRx Inc. today announced positive regulatory feedback from its Type B pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of cethromycin hydrochloride (Cethromycin HCl) for liver-stage malaria.